XNASNPCE
Market cap356mUSD
Jan 10, Last price
11.94USD
1D
-0.58%
1Q
80.64%
IPO
-53.07%
Name
Neuropace Inc
Chart & Performance
P/E
—
P/S
5.45
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
65m
+43.72%
Net income
-33m
L-38.25%
CFO
-20m
L-46.56%
Earnings
Mar 03, 2025
Profile
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 65,421 43.72% | 45,520 0.75% | |||
Cost of revenue | 38,077 | 34,973 | |||
Unusual Expense (Income) | |||||
NOPBT | 27,344 | 10,547 | |||
NOPBT Margin | 41.80% | 23.17% | |||
Operating Taxes | 6,288 | ||||
Tax Rate | 59.62% | ||||
NOPAT | 27,344 | 4,259 | |||
Net income | (32,956) -38.25% | (53,370) 40.05% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 7,888 | 837 | |||
BB yield | -2.96% | -2.28% | |||
| Debt | |||||
Debt current | 3,254 | 1,415 | |||
Long-term debt | 86,209 | 85,208 | |||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | 23,009 | 9,092 | |||
| Cash flow | |||||
Cash from operating activities | (19,701) | (36,869) | |||
CAPEX | (173) | (603) | |||
Cash from investing activities | 23,027 | 23,797 | |||
Cash from financing activities | 8,127 | 490 | |||
FCF | 26,190 | (13,853) | |||
| Balance | |||||
Cash | 66,454 | 77,409 | |||
Long term investments | 122 | ||||
Excess cash | 63,183 | 75,255 | |||
Stockholders' equity | (503,781) | (471,936) | |||
Invested Capital | 598,559 | 576,481 | |||
ROIC | 4.65% | 0.86% | |||
ROCE | 28.85% | 10.09% | |||
| EV | |||||
Common stock shares outstanding | 25,852 | 24,595 | |||
Price | 10.31 591.95% | 1.49 -85.22% | |||
Market cap | 266,532 627.31% | 36,646 -85.13% | |||
EV | 289,541 | 45,738 | |||
EBITDA | 28,949 | 13,534 | |||
EV/EBITDA | 10.00 | 3.38 | |||
Interest | 8,517 | 7,529 | |||
Interest/NOPBT | 31.15% | 71.39% | |||